These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16582505

  • 1. [Mechanism of osteoblastic bone metastasis of prostate cancer].
    Yonou H, Ogawa Y, Ochiai A.
    Clin Calcium; 2006 Apr; 16(4):557- 64. PubMed ID: 16582505
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism.
    Yonou H, Aoyagi Y, Kanomata N, Kamijo T, Oda T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.
    Biochem Biophys Res Commun; 2001 Dec 21; 289(5):1082-7. PubMed ID: 11741302
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A.
    Prostate; 2006 Nov 01; 66(15):1573-84. PubMed ID: 16927388
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
    Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC.
    Clin Cancer Res; 2006 Mar 01; 12(5):1420-30. PubMed ID: 16533764
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M.
    Prostate; 2007 Jun 01; 67(8):840-8. PubMed ID: 17394194
    [Abstract] [Full Text] [Related]

  • 6. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.
    Prostate; 2009 Aug 01; 69(11):1222-34. PubMed ID: 19434660
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET, Brown J.
    J Cell Biochem; 2004 Mar 01; 91(4):718-29. PubMed ID: 14991763
    [Abstract] [Full Text] [Related]

  • 8. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen.
    Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF.
    J Cell Physiol; 2005 Feb 01; 202(2):361-70. PubMed ID: 15389580
    [Abstract] [Full Text] [Related]

  • 9. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.
    Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I.
    Anticancer Res; 1997 Feb 01; 17(3A):1461-5. PubMed ID: 9179184
    [Abstract] [Full Text] [Related]

  • 10. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
    Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN, Vuopala KS, Harris KW, Selander KS.
    Prostate; 2009 May 01; 69(6):652-61. PubMed ID: 19152406
    [Abstract] [Full Text] [Related]

  • 11. Pathogenesis of osteoblastic bone metastases from prostate cancer.
    Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D.
    Cancer; 2010 Mar 15; 116(6):1406-18. PubMed ID: 20108337
    [Abstract] [Full Text] [Related]

  • 12. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET.
    Cancer Res; 2005 Sep 15; 65(18):8274-85. PubMed ID: 16166304
    [Abstract] [Full Text] [Related]

  • 13. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR.
    J Orthop Res; 2005 Nov 15; 23(6):1475-83. PubMed ID: 16005175
    [Abstract] [Full Text] [Related]

  • 14. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
    Yonou H, Ochiai A, Goya M, Kanomata N, Hokama S, Morozumi M, Sugaya K, Hatano T, Ogawa Y.
    Prostate; 2004 Mar 01; 58(4):406-13. PubMed ID: 14968441
    [Abstract] [Full Text] [Related]

  • 15. MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells.
    Katopodis H, Philippou A, Tenta R, Doillon C, Papachroni KK, Papavassiliou AG, Koutsilieris M.
    Anticancer Res; 2009 Oct 01; 29(10):4013-8. PubMed ID: 19846944
    [Abstract] [Full Text] [Related]

  • 16. Canine prostate stimulates osteoblast function using the endothelin receptors.
    LeRoy BE, Sellers RS, Rosol TJ.
    Prostate; 2004 May 01; 59(2):148-56. PubMed ID: 15042615
    [Abstract] [Full Text] [Related]

  • 17. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M.
    Cancer Res; 2005 Oct 01; 65(19):8818-25. PubMed ID: 16204052
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5.
    Maeda H, Yonou H, Yano K, Ishii G, Saito S, Ochiai A.
    Biochem Biophys Res Commun; 2009 Apr 10; 381(3):311-6. PubMed ID: 19250630
    [Abstract] [Full Text] [Related]

  • 19. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
    Lai TH, Fong YC, Fu WM, Yang RS, Tang CH.
    Prostate; 2008 Sep 01; 68(12):1341-53. PubMed ID: 18512729
    [Abstract] [Full Text] [Related]

  • 20. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.
    Koutsilieris M, Sourla A, Pelletier G, Doillon CJ.
    J Bone Miner Res; 1994 Nov 01; 9(11):1823-32. PubMed ID: 7863832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.